Angiotensin-(1-7) decreases glycated albumin-induced endothelial interleukin-6 expression via modulation of miR-146a

Biochemical and Biophysical Research Communications

Volumn 430, Issue 3, 2013, Pages 1157-1163

  Wang, Huang Joe ^a,b   Lo, Wan Yu ^b,c,d   Lin, Li Jen ^c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

Angiotensin (1 7); Endothelial cells; Glycated albumin; Interleukin 6; MiR 146a

Indexed keywords

ANGIOTENSIN[1-7]; GLYCOSYLATED ALBUMIN; INTERLEUKIN 6; MESSENGER RNA; MICRORNA 146A;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION;

ANGIOTENSIN I; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYTOPROTECTION; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; HUMANS; INTERLEUKIN-6; MICRORNAS; PEPTIDE FRAGMENTS; SERUM ALBUMIN;

EID: 84872492853     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.12.018     Document Type: Article

References (32)

1. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
2. Goldin A., Beckman J.A., Schmidt A.M., et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
3. Rondeau P., Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie 2011, 93:645-658.
4. Kim K.J., Lee B.W. The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab. J. 2012, 36:98-107.
5. Lu L., Pu L.J., Zhang Q., et al. Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis 2009, 206:540-545.
6. Freedman B.I., Andries L., Shihabi Z.K., et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin. J. Am. Soc. Nephrol. 2011, 6:1635-1643.
7. A.J. Ferreira, T.M. Murca, R.A. Fraga-Silva et al., New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis, Int. J. Hypertens. (2012) 147825.
8. Sampaio W.O., Henrique de Castro C., Santos R.A., et al. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007, 50:1093-1098.
9. Alenina N., Xu P., Rentzsch B., et al. Genetically altered animal models for Mas and angiotensin-(1-7). Exp. Physiol. 2008, 93:528-537.
10. Tesanovic S., Vinh A., Gaspari T.A., et al. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1606-1613.
11. Yudkin J.S., Kumari M., Humphries S.E., et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 2000, 148:209-214.
12. Schuett H., Luchtefeld M., Grothusen C., et al. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb. Haemostasis 2009, 102:215-222.
13. Schram M.T., Chaturvedi N., Schalkwijk C.G., et al. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 2005, 48:370-378.
14. Siomi H., Siomi M.C. On the road to reading the RNA-interference code. Nature 2009, 457:396-404.
15. Li L., Chen X.P., Li Y.J. MicroRNA-146a and human disease. Scand. J. Immunol. 2010, 71:227-231.
16. Bhaumik D., Scott G.K., Schokrpur S., et al. MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging (Albany, NY) 2009, 1:402-411.
17. Bhaumik D., Scott G.K., Schokrpur S., et al. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008, 27:5643-5647.
18. Wang H.J., Lo W.Y., Lu T.L., et al. (-)-Epigallocatechin-3-gallate decreases thrombin/paclitaxel-induced endothelial tissue factor expression via the inhibition of c-Jun terminal NH2 kinase phosphorylation. Biochem. Biophys. Res. Commun. 2010, 391:716-721.
19. Hattori Y., Suzuki M., Hattori S., et al. Vascular smooth muscle cell activation by glycated albumin (Amadori adducts). Hypertension 2002, 39:22-28.
20. Liu Y., Liang C., Liu X., et al. AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-kappaB pathways. Atherosclerosis 2010, 208:34-42.
21. Cohen M.P., Shea E., Chen S., et al. Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J. Lab. Clin. Med. 2003, 141:242-249.
22. Rodino-Janeiro B.K., Gonzalez-Peteiro M., Ucieda-Somoza R., et al. Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: molecular correlate of diabetic vasculopathy. Diabetes. Metab. Res. Rev. 2010, 26:550-558.
23. Benter I.F., Yousif M.H., Dhaunsi G.S., et al. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am. J. Nephrol. 2008, 28:25-33.
24. Feng B., Chen S., McArthur K., et al. MiR-146a-Mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 2011, 60:2975-2984.
25. Karolina D.S., Armugam A., Tavintharan S., et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS ONE 2011, 6:e22839.
26. Balasubramanyam M., Aravind S., Gokulakrishnan K., et al. Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol. Cell. Biochem. 2011, 351:197-205.
27. Taganov K.D., Boldin M.P., Chang K.J., et al. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 2006, 103:12481-12486.
28. Li N., Xu X., Xiao B., et al. H. pylori related proinflammatory cytokines contribute to the induction of miR-146a in human gastric epithelial cells. Mol. Biol. Rep. 2012, 39:4655-4661.
29. Larner-Svensson H.M., Williams A.E., Tsitsiou E., et al. Pharmacological studies of the mechanism and function of interleukin-1beta-induced miRNA-146a expression in primary human airway smooth muscle. Respir. Res. 2010, 11:68.
30. Hsieh C.H., Rau C.S., Jeng S.F., et al. Identification of the potential target genes of microRNA-146a induced by PMA treatment in human microvascular endothelial cells. Exp. Cell. Res. 2010, 316:1119-1126.
31. Chen T., Li Z., Jing T., et al. MicroRNA-146a regulates the maturation process and pro-inflammatory cytokine secretion by targeting CD40L in oxLDL-stimulated dendritic cells. FEBS Lett. 2011, 585:567-573.
32. Yang K., He Y.S., Wang X.Q., et al. MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett. 2011, 585:854-860.